Inhaled pulmonary vasodilators for persistent pulmonary hypertension of the newborn: safety issues relating to drug administration and delivery devices
Nathan Cosa,1 Edward Costa Jr2 1Department of Respiratory Care, Banner Desert Medical Center, Cardon Children's Medical Center, Mesa, AZ, 2Department of Medical Affairs, Mallinckrodt Pharmaceuticals, Hampton, NJ, USA Abstract: Treatment for persistent pulmonary hypertension of the newborn (...
Guardado en:
Autores principales: | Cosa N, Costa E Jr |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/483058e58e7b48f687b1e780459d9d73 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The pharmacological management of erectile dysfunction – Update 2016
por: André Marais
Publicado: (2016) -
Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
por: Abraham Tettey, et al.
Publicado: (2021) -
Fractional exhaled nitric oxide-measuring devices: technology update
por: Maniscalco M, et al.
Publicado: (2016) -
Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging
por: Salas M, et al.
Publicado: (2021) -
Compatibility and Safety Implications Associated with Interfacing Medical Devices in Neonatal Respiratory Care: A Case Example Using the Inhaled Nitric Oxide Delivery System
por: DeWitt AL, et al.
Publicado: (2021)